AstraZeneca
- Awards
- 5
- Value outside frameworks
- Framework places and shared awards only
- Framework places
- 4
- Shared awards
- 1
Values exclude VAT where the notices give it, and only values in pounds are added up. A framework place carries the framework's whole ceiling, shared with the other suppliers on it, so framework places are counted rather than added up; so are awards made to several suppliers together. Every award here is a framework place or shared.
Awards
| Procurement | Buyer | Value | Date |
|---|---|---|---|
| NHS Framework Agreement for Branded medicines - National framework | NHS England | £526,000,000 | 16 May 2022 |
| NHS Framework for the North of England, Branded Medicine framework | NHS England | £238,913,892 | 7 Feb 2022 |
| NHS Framework for Midlands and East, Branded Medicines - Tranche A and Annual framework | NHS England | £216,078,796 | 7 Feb 2022 |
| NHS Framework Agreement, Branded Medicines for London and South of England framework | NHS England | £558,521,926 | 19 Aug 2021 |
| NHS National Pharmaceuticals - Fulvestrant, Darunavir and Imatinib shared | NHS England | £17,300,000 | 4 Jan 2021 |
Top buyers
| Buyer | Awards | Value |
|---|---|---|
| NHS England | 5 | - |
By number of awards. Value is the total of awards made to this supplier alone outside frameworks, excluding VAT where the notices give it.